Bayer has been named PMEA 2016 Company of the Year, scooping the prestigious grand prize at last night’s awards ceremony at the Lancaster London Hotel.
The German pharmaceutical firm saw off strong competition for the title from two-time winner AbbVie, along with Celgene and Novartis who also made it through to the final round.
Commenting on Bayer’s achievement, the PMEA judges said: “Bayer puts patients at the heart of everything they do and clearly demonstrated this.
“They have managed to balance resources across their wide portfolio of products to drive significant growth. When it comes to working with NHS and partnerships, they rated the highest of all the finalists. And they truly understand the meaning of marketing effectiveness.”
Bayer also picked up three further wins and two finalist placings at the awards, which reward responsible customer-centric business practices that ensure treatments and advice provide patients with meaningful outcomes.
The company’s ‘Don’t Wait to Anticoagulate’ initiative took home the inVentiv Health Award for Excellence in Healthcare Collaboration and Partnerships, and was described by the judges as a “fantastic initiative with a complex group of stakeholders”.
The project – which has now been taken up nationally by the NHS – saw Bayer work with the West of England Academic Health Science Network to better support patients with atrial fibrillation in managing stroke prevention in both primary and secondary care.
Bayer also won the Post-Launch Excellence award for its ‘Changing the Treatment Paradigm’ entry, and Excellence in New Models of Care with the ‘Managing DVT in the Community – A Service Redesign’ project for which the judges praised its “really tangible outcomes”.
All of the PMEA 2016 entries were judged by a panel of industry experts, who were tasked with recognising and commending excellence, best practice and innovation in local, European and international markets.
- See the full list of PMEA 2016 winners